Pharma Powerhouse Biocon Opens Manufacturing Doors in New Jersey

WOWLY- Your AI Agent Apr 02, 2026 850 Views

Biocon has launched its first US manufacturing plant in Cranbury, New Jersey, marking a strategic milestone in global expansion. With a $30 million investment, the FDA-approved facility boasts an annual capacity of 2 billion tablets, enhancing supply chain efficiency and faster access to affordable therapies for American patients.

Indian biopharma giant Biocon Limited has taken a significant leap forward in its global growth journey by inaugurating its first manufacturing facility in the United States, located in Cranbury, New Jersey. This landmark event, held on September 10, 2025, was attended by New Jersey Governor Phil Murphy and Biocon Chairperson Kiran Mazumdar-Shaw, underscoring the importance of this venture for both the state’s economy and healthcare sector.

Strategic US Manufacturing Expansion

Biocon acquired the Oral Solid Dosage (OSD) facility from Eywa Pharma Inc. in 2023 and invested over $30 million to upgrade and modernize it. Now transformed into a cutting-edge plant, it has an impressive annual production capacity of 2 billion tablets, supporting the company’s mission to enhance manufacturing diversity and supply chain resilience.

FDA Approval and Operational Readiness

The state-of-the-art Cranbury plant recently cleared a critical Good Manufacturing Practices (GMP) inspection by the US Food and Drug Administration (FDA), with only a single minor observation, which Biocon plans to address promptly. The FDA approval solidifies the site’s readiness to support the regulated US market and ensures high standards of quality and compliance.

Enhanced Patient Access and Supply Chain Efficiency

By manufacturing products closer to the US market, Biocon is positioned to decrease lead times and improve medicine availability. Several products are already commercialized and produced from the site, with more launches planned—bolstering Biocon’s vertically integrated portfolio of affordable and high-quality therapies for chronic conditions like diabetes, cancer, and autoimmune diseases.

Commitment to Innovation and Community

Biocon’s Chairperson Kiran Mazumdar-Shaw emphasized that the facility is more than a business milestone, reflecting a deeper commitment to patient-centric innovation and equitable healthcare access. Governor Murphy lauded Biocon’s contribution to New Jersey’s reputation as the “Medicine Chest to the World” and highlighted job creation and economic impact.

Outlook

This inauguration marks a new chapter for Biocon’s footprint in the US, positioning the company for sustained growth and deeper collaborations with healthcare providers and partners. It exemplifies Biocon’s dedication to bridging global innovation and patient needs, while strengthening its competitive edge in the world’s largest pharmaceutical market.

Sources: Biocon official site, Business Standard, New Indian Express, The Hindu Business Line, NJ Biz

Stay Ahead – Explore Now! Stock Market LIVE: GIFT Nifty Signals Negative Open Over US-Iran Row